Skip to search formSkip to main contentSkip to account menu

CD19CAR-CD3zeta-4-1BB-expressing Autologous T-lymphocytes

Known as: CTL019, CTL019 T-cells, CART-19 
Autologous T-lymphocytes transduced with a modified lentiviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 scFv… 
National Institutes of Health

Related topics

Related topics

5 relations
Antigen SensitizationCytotoxic T-LymphocytesNCIt Antineoplastic Agent TerminologyT-Cell Activation

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
CD19‐DIRECTED CAR T CELL THERAPY (CTL019) FOR RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL AND FOLLICULAR LYMPHOMAS: FOUR YEAR OUTCOMES
Takeda, Teva, Verastem. Gasiorowski, R: Honoraria: Novartis, MSD, Takeda, Abbvie. Illés, A: Consultant Advisory Role: Janssen… 
2018
2018
Anti-CD 19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma
BACKGROUND. Multiple myeloma is usually fatal due to serial relapses that become progressively refractory to therapy. CD19 is… 
2016
2016
Efficacy of humanized CD19-targeted chimeric antigen receptor (CAR)-modified T cells in children with relapsed ALL.
3007Background: Targeted immunotherapy with CTL019, CD19-specific CAR-modified T cells, can produce potent, sustained responses… 
2016
2016
Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Poor Prognosis, Relapsed or Refractory CD19+ Follicular Lymphoma: Prolonged Remissions Relative to…
BACKGROUND: Patients (pts) with follicular lymphoma (FL) who have progression of disease within 2 years of immunochemotherapy… 
2015
2015
Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL
Background Targeted immunotherapy with T cells expressing a chimeric antigen receptor (CAR) can produce dramatic anti-tumor… 
2015
2015
Safety and efficacy of anti-CD19 chimeric antigen receptor (CAR)-modified autologous T cells (CTL019) in advanced multiple myeloma.
8517 Background: CTL019, a 2nd-generation anti-CD19 CAR transduced via lentiviral vector, can induce regression of refractory B… 
2014
2014
FDA approves first bispecific
were initially developed by Micromet, which was acquired by Amgen in 2012 for US$1.16 billion. Financial analysts expect sales of… 
2014
2014
Phase IIa Trial of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas
BACKGROUND: Autologous T cells genetically modified to express a chimeric antigen receptor consisting of an external anti-CD19… 
2013
2013
Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019 cells) Have Long-Term Persistence and Induce Durable Responses In Relapsed, Refractory CLL
Background Chimeric antigen receptors (CARs) combine the antigen recognition domain of an antibody with intracellular signaling… 
2013
2013
T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Produce Significant In Vivo Proliferation, Complete Responses and Long-Term Persistence Without Gvhd In Children and…
![Graphic][1] Background CARs combine a single chain variable fragment (scFv) of an antibody with intracellular signaling… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)